Validation of the Freezing of Gait Questionnaire in patients with Parkinson's disease

Nir Giladi, Joseph Tal, Tali Azulay, Oliver Rascol, David J. Brooks, Eldad Melamed, Wolfgang Oertel, Werner H. Poewe, Fabrizio Stocchi, Eduardo Tolosa

Research output: Contribution to journalArticlepeer-review


To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥ 1) and 44.1% using UPDRS item 14 (≥1) (P <0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalMovement Disorders
Issue number5
Publication statusPublished - Apr 15 2009


  • Freezing of gait
  • Parkinson's disease
  • Rasagiline
  • Validation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)


Dive into the research topics of 'Validation of the Freezing of Gait Questionnaire in patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this